【专家协会推荐优选减肥药预防心脏病诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL_老虎社区_美港股上老虎

【专家协会推荐优选减肥药预防心脏病诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL

智通财经06-21

【专家协会推荐优选减肥药预防心脏病诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术的干预措施。”

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

赛虎
·06-22
礼来减肥药物有哪些服用禁忌？比如30年前生过疑似胰腺炎的疾病可以服用吗？
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2545002291?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-21 15:12","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2545002291","market":"us","top_or_hot":-1,"title":"【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】</b>智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术的干预措施。”                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-21 15:12 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0354030511.USD","symbol_name":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2545002291","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545002291","pubTimestamp":1750489938,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159891":"医疗","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LLY":"礼来","BK4588":"碎股","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","NVO":"诺和诺德","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU0079474960.USD":"联博美国增长基金A","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","BK4516":"特朗普概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC"},"translate_title":"[The expert association recommends the preferred weight-loss pills to prevent heart disease, Noli is expected to benefit] Zhitong Finance APP learned that weight-loss drug manufacturers Novo Nordisk (NVO.US) and Eli Lilly (LL","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"LLY":1,"NVO":1},"content_text":"【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术的干预措施。”","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":448623099412840,"gmtCreate":1750553519658,"gmtModify":1750559983436,"author":{"id":"39868285618939","authorId":"39868285618939","name":"赛虎","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"39868285618939","authorIdStr":"39868285618939"},"htmlText":"礼来减肥药物有哪些服用禁忌？比如30年前生过疑似胰腺炎的疾病可以服用吗？","listText":"礼来减肥药物有哪些服用禁忌？比如30年前生过疑似胰腺炎的疾病可以服用吗？","text":"礼来减肥药物有哪些服用禁忌？比如30年前生过疑似胰腺炎的疾病可以服用吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/448623099412840","repostId":2545002291,"repostType":2,"repost":{"id":"2545002291","kind":"live","pubTimestamp":1750489938,"share":"https://www.laohu8.com/m/news/2545002291?lang=&edition=full","pubTime":"2025-06-21 15:12","market":"us","language":"zh","title":"【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL","url":"https://stock-news.laohu8.com/highlight/detail?id=2545002291","media":"智通财经","summary":"【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防","content":"<html><body><div>\n<div>\n<b>【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】</b>智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术的干预措施。”                </div>\n</div></body></html>","source":"live_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LL\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-21 15:12 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"159891":"医疗","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LLY":"礼来","BK4588":"碎股","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","NVO":"诺和诺德","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU0079474960.USD":"联博美国增长基金A","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","BK4516":"特朗普概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC"},"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2545002291","content_text":"【专家协会推荐优选减肥药预防心脏病 诺礼有望受益】智通财经APP获悉，减肥药物生产商诺和诺德(NVO.US)和礼来(LLY.US)的股票可能会受益，因为美国心脏病学会(ACC)建议，肥胖患者在选择预防心脏病的治疗方案时，肥胖症药物应作为主要选项之一。该非营利性医疗协会在周五发布的最新《简明临床指南》中指出，与肥胖相关的心脏疾病(如高血压)“越来越多地可以通过现代减肥药物来治疗，其风险要低于基于手术的干预措施。”","news_type":1,"symbols_score_info":{"159891":1,"LLY":1,"NVO":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}